Innovation Key to Reversing Decline in Routine Cancer Screenings
A new survey reveals declining cancer screening rates among U.S. adults, but shows strong interest in innovative screening methods.
A new survey reveals declining cancer screening rates among U.S. adults, but shows strong interest in innovative screening methods.
AMP has published consensus best practice recommendations to standardize HRD testing in clinical laboratories.
Quest Diagnostics is partnering with MD Anderson Cancer Center to develop a lab-based blood test for cancer that uses protein biomarkers.
Guardant Health’s Shield MCD test has received FDA Breakthrough Device designation for its ability to detect multiple cancer types.
Read MorePersonalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read MoreNew Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read MoreLabcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read MoreSAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read MoreHologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read MoreForesight Diagnostics announced the independent validation of its CLARITY MRD assay, showing strong prognostic performance.
Read MoreA strategic partnership has formed to accelerate the development a test for early ovarian cancer diagnosis using AI-powered analytics.
Read MoreResearchers developed an AI-driven blood test, ARTEMIS-DELFI, that detects pancreatic cancer treatment response faster and more accurately.
Read MoreThe FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MoreA groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read MoreOncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough.
Read MoreTeal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
Read MoreNew predictive algorithms using routine health data and blood tests significantly improve early detection of 15 cancers.
Read MoreA new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Read More